Sertraline treatment of major depression in patients with acute MI or unstable angina

Ah, Glassman; O’Connor, Christopher M; Califf, R.M.

doi:10.1016/s1062-1458(02)00908-x

Cited by 351 publications

(524 citation statements)

References 0 publications

Supporting

Mentioning

475

Contrasting

Unclassified

Order By: Relevance

“…Depression and hopelessness have been studied as independent predictors of increased deaths in observational studies, which have also drawn attention to the link among depression, cardiovascular disease, and death (1,2). Intervention trials, such as the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) trial (9,10) and the Sertraline Anti-Depressant Heart Attack Randomized Trial (SADHART) (11), have focused on depression treatment for persons with advanced cardiovascular disease (7). The ENRICHD trial did not show any benefit on risk for death over a 40-month follow-up, and researchers did not report separate analyses for patients with major depression.…”

Section: Discussionmentioning

confidence: 99%

“…Secondary analysis from ENRICHD showed that an antidepressant prescription (a selective serotonin reuptake inhibitor) was associated with reduction in all-cause mortality (12). The SADHART reported a statistically nonsignificant beneficial trend after 24 weeks for a combined outcome of death and nonfatal cardiovascular events for patients with a major depression disorder after myocardial infarction (11). Perhaps the target population represented by the ENRICHD and SADHART samples were further along in the pathway between depression and death than were participants in PROSPECT, whose sample was derived from community practices.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of a Primary Care Practice–Based Depression Intervention on Mortality in Older Adults

et al. 2007

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Effect of a Primary Care Practice–Based Depression Intervention on Mortality in Older Adults

et al. 2007

View full text Add to dashboard Cite

“…40 A total of 369 participants who had depression after hospitalization for acute coronary syndrome were randomly assigned to the selective serotonin reuptake inhibitor (SSRI) antidepressant medication sertraline vs placebo. Of these, 260 completed the 16-week trial.…”

Section: Does Pharmacotherapy For Depression Prevent Cardiac Events?mentioning

confidence: 99%

“…43 In summarizing the available evidence, recent Cochrane reviews have concluded there is not sufficient evidence that psychotherapy for depression improves outcomes in patients with CHD, 44 and no study has examined whether treatment for depression improves outcomes in patients with CHF. 45 Thus, although both psychological and pharmacological interventions reduce anxiety and depression, 40,44 it remains unknown whether therapy for depression improves cardiovascular outcomes. A large randomized trial testing the effect of antidepressant medication on incidence or recurrence of cardiac events would help to answer this question.…”

Section: Does Psychotherapy For Depression Prevent Cardiac Events?mentioning

confidence: 99%

Depression and Cardiovascular Disease

Whooley¹

2006

JAMA

216

163

View full text Add to dashboard Cite

Major depressive disorder is a risk factor for the development of incident coronary heart disease events in healthy patients and for adverse cardiovascular outcomes in patients with established heart disease. Depression is present in 1 of 5 outpatients with coronary heart disease and in 1 of 3 outpatients with congestive heart failure, yet the majority of cases are not recognized or appropriately treated. It is not known whether treating depression improves cardiovascular outcomes, but antidepressant treatment with selective serotonin reuptake inhibitors is generally safe, alleviates depression, and improves quality of life. This article evaluates the importance of major depression in patients with cardiovascular disease, and provides practical guidance for identifying and treating this disorder. CASE PRESENTATIONA 58-year-old man with a history of coronary heart disease (CHD), type 2 diabetes mellitus, hypertension, smoking, and alcohol dependence presented for routine medical care. He had initially sought medical attention for exertional angina 5 years previously, at which time he underwent exercise treadmill testing with thallium that was positive for reversible perfusion defects in the anterior, septal, and inferior walls. Subsequent coronary angiography revealed diffuse heavy calcifications in the left anterior descending artery with a moderate lesion prior to the first diagonal. Several major septal perforators had significant lesions at their origins. In the dominant right coronary artery, there were diffuse calcifications but no significant lesions. The left circumflex and large ramus intermedius were free of discrete lesions. Left ventricular function was normal.The patient underwent single-vessel (left internal mammary artery to left anterior descending artery) coronary artery bypass grafting (CABG) surgery. He was prescribed atenolol 100 mg/ d, lisinopril 40 mg/d, lovastatin 80 mg/d, aspirin 325 mg/d, metformin 850 mg 3 times a day, and glipizide 10 mg 2 times a day. Despite being nonadherent to his prescribed medications, he remained stable for 5 years, but then one day, while doing household chores, he suddenly developed chest pressure, shortness of breath, and diaphoresis that lasted 12 hours. On admission to the hospital his troponin I was elevated and peaked at 0.7 ng/mL (normal, <0.05 ng/mL), consistent with a myocardial infarction (MI). His electrocardiogram had not changed.

show abstract

“…However, the rigid inclusion/ exclusion criteria used in efficacy trials limit its generalizability to most clinical practice. As safety data continue to be evaluated, it will be important to also examine the results of trials of antidepressants in old-old populations and populations with specific medical illnesses, such as the use of sertraline after acute myocardial infarction (Glassman et al, 2002).…”

Section: Safety and Tolerability Of Antidepressants In The Elderly Pomentioning

confidence: 99%

A Systematic Review of Antidepressant Placebo-Controlled Trials for Geriatric Depression: Limitations of Current Data and Directions for the Future

Taylor

Doraiswamy

2004

Neuropsychopharmacol

View full text Add to dashboard Cite

Depression in the elderly is a major public health problem as untreated depression adversely impacts comorbid illnesses. It is important to develop safe and effective antidepressant therapies for older individuals. We performed a systematic review of all published randomized, placebo-controlled antidepressant medication trials in populations over age 55 years. Papers were obtained via MEDLINE (1966( -August 2003 and PSYCINFO (1872-August 2003. Unpublished trials, trials examining nonpharmacologic interventions, and papers reporting post hoc analyses were not included in this review unless they provided new insights. A total of 18 placebo-controlled trials examining acute efficacy met our criteria. The combined sample size in these studies was 2252. The mean sample size was 51 (range 20-728) and mean trial duration was 7 weeks. A total of 12 trials examined tricyclic antidepressants (TCAs), five trials examined selective serotonin reuptake inhibitors (SSRIs), two trials examined bupropion, and one trial examined mirtazapine. There were no published trials of venlafaxine or nefazodone. In all, 71.5% of trials reported significantly greater efficacy with drug than placebo. In conclusions, there is a paucity of published controlled antidepressant trials in the elderly. Most published studies examine small sample sizes and do not include common comorbid conditions. Efficacy studies examining relapse prevention are lacking. Large placebo response rates, lack of controlled head to head comparisons, and other methodological design differences make crosstrial comparisons difficult. Large simple studies are urgently needed to address the unmet needs for data on safety and efficacy of antidepressants in this population.

show abstract

Sertraline treatment of major depression in patients with acute MI or unstable angina

Cited by 351 publications

References 0 publications

The Effect of a Primary Care Practice–Based Depression Intervention on Mortality in Older Adults

The Effect of a Primary Care Practice–Based Depression Intervention on Mortality in Older Adults

Depression and Cardiovascular Disease

A Systematic Review of Antidepressant Placebo-Controlled Trials for Geriatric Depression: Limitations of Current Data and Directions for the Future

Contact Info

Product

Resources

About